Journal

The global burden of chronic kidney disease

Read time: 1 mins

Published:28th Feb 2020

Author: Cockwell P, Fisher LA.

Source: The Lancet

Ref.:Lancet. 2020 Feb 29;395(10225):662-664.

DOI:10.1016/S0140-6736(19)32977-0

Chronic kidney disease (CKD) is a non-communicable disease usually caused by diabetes and hypertension.¹Cardiovascular disease is the major cause of the early morbidity and mortality sustained by patients with CKD. The severity of CKD can be quantified by a low serum creatinine-based estimated glomerular filtration rate (eGFR), which indicates excretory kidney function, and raised urinary albumin measured by the urinary albumin-to-creatinine ratio (ACR), which is a marker of kidney damage.²The Kidney Disease: Improving Global Outcomes classification system for staging CKD is based on eGFR and ACR and is widely used in clinical practice.

Access full article

Hyperkalaemia

Containing relevant Learning Zones, guidelines, trials and news.

A digital image of two human kidneys, stylised in blue and red

Chronic Kidney Disease

Containing relevant Learning Zones, guidelines, trials and news.

Digital close up of human kidney glomerulus and the Bowman Capsule

Glomerulonephritis

Containing relevant Learning Zones, guidelines, trials and news.

Featured Learning Zones

patient receiving dialysis, hospital image

Learning Zone

Chronic Kidney Disease Learning Zone

Chronic Kidney Disease (CKD) is a disease that can often lead to a need for haemodialysis and kidney transplantation. New CKD treatments are emerging which focus on delaying CKD disease progression and the need for transplantation.

You may be interested in...

Guideline

Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) for the diagnosis of Cushing's syndrome: Genetics of Cushing's syndrome

Recent advancements in high-throughput sequencing have significantly enhanced our understanding of the genetics behind Cushing’s syndrome. Experts from the French Society of Endocrinology and French Society of Endocrinology and Pediatric Endocrinology reviewed genetic predispositions, resulting in a consensus statement on screening for Cushing disease and adrenal Cushing’s syndrome. Discover their key findings and recommendations.

Guideline

Consensus on diagnosis and management of Cushing's disease: a guideline update

The Pituitary Society’s Consensus Workshop brought together over 50 experts to refine the clinical approach to Cushing’s disease. This comprehensive review and collaborative discussion resulted in updated recommendations for diagnosis, treatment, and management, highlighting key areas for future research. Discover the latest consensus on optimizing patient outcomes in Cushing’s disease.

Guideline

Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024

Background and purpose: Two novel enzyme replacement therapies (ERTs), studied in phase 3 trials in late-onset Pompe patients, reached marketing authorization by the European Medicines Agency in 2022 and 2023. The European Pompe Consortium (EPOC) updates and extends the scope of the 2017 recommendations for starting, switching and stopping ERT.